AE	Adverse Event
AUC	Area below the Serum Concentration Curve
AUCO-t	Last Time Point
BC	Breast Cancer
CHR	Complete Histological Response
CI	Confidence Intervals
Cmax	Maximum Measured Concentration
Ctrough	Concentration Trough Plasma Levels
DFS	Disease-Free Survival
EBC	Early Breast Cancer
EFS	Event-Free Survival
EGFR	Epidermal Growth Factor Receptor
EMA	The European Medicines Agency
FcγRIIIa	FcγR IIIa Receptor
FDA	The United States Food and Drug Administration Agency
FDP	Free Disease Progression
FEC	Fluorouracil, Epirubicin, Cyclophosphamide
HER2+	HER2-positive
HER+ EBC	HER+ Early BC
HER2+ MBC	HER+ Metastatic BC
IVT-mRNA	In Vitro-Transcribed mRNA
MAPK	Mitogen-Activated Protein Kinase Pathway
MKI67	Ki-67 Cell Proliferation Index
MBC	Metastatic Breast Cancer
OS	Overall Survival
OR	Overall Response
ORR	Objective Response Rate
pCR	Pathological Complete Response
PFS	Progression-Free Survival
PLCγ	Phospholipase Cγ
PI3K	Phosphatidylinositol 3-kinase Pathway
PR	Partial Response
SAE	Serious Adverse Event
TEAE	Treatment-Emergent Adverse Events
TTD	Time to Treatment Discontinuation
TRZ	Trastuzumab